In a meta-analysis of pooled individual participant data from 5 double-blind placebo-controlled RCTs, antihypertensive treatment was associated with a lower dementia risk compared with placebo.
AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.
AHA 2022 By participating in a mindfulness-based program, individuals with elevated office blood pressure (BP) could lower their systolic BP by 4.5 mmHg within 6 months compared with enhanced usual care.
AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.
AHA 2022 A phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of NTLA-2001, a CRISPR/Cas9-based in vivo gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy.
AHA 2022 Prof. Gillmore shares the results of a phase 1 study that showed that treatment with the investigational CRISPR/Cas9-based gene editing therapy NTLA-2001 led to a TTR reduction of ≥90% by day 28 in patients with transthyretin amyloidosis with cardiomyopathy.
In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.
CSI Barcelona What is CODE-EHR and why has this framework been developed? Prof. Asselbergs gives a brief overview in response to questions of Joris Holtrop.
CSI Barcelona What is the risk of CVD in patients with autoimmune diseases and has this yet been incorporated in the guidelines? Marga Helmink interviews Prof. Sattar on this topic.
The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?
In a population-based cohort study, the clinical performance of the 2021 ESC Guidelines for CVD prevention on eligibility of primary prevention with statins was compared with that of the 2019 ESC/EAS, 2016 NICE, and 2013 ACC/AHA guidelines.
Most guidelines include total cholesterol and HDL-c levels in risk prediction of ischemic and atherosclerotic heart disease, but not remnant cholesterol levels. Does inclusion of elevated remnant cholesterol levels improves prediction?